{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:43:22Z","timestamp":1789955002641,"version":"4.0.1"},"reference-count":36,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2017,7,11]]},"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Previous studies assessing breast cancer risk in families with Lynch syndrome (LS) have yielded conflicting results. Furthermore, conclusions are limited by small sample size and few breast cancer outcomes. This study assesses breast cancer risk in a large prospectively followed LS cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pedigrees of 325 unrelated families with LS within the Familial Gastrointestinal Cancer Registry in Canada were examined for breast cancer diagnoses. Standardised incidence ratios (SIR) and lifetime cumulative incidence calculations were used to compare the incidence of breast cancer in mutation carriers with the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-one mutation carriers diagnosed with breast cancer belonging to 34 unrelated families were identified. Mean age at diagnosis was 54 years. The mutation distribution among the LS patients with breast cancer was statistically different from those without breast cancer (p=0.015), reflecting the predominance of <jats:italic>MSH2<\/jats:italic> mutations among affected patients (74%). Eighty-eight per cent of LS families with breast cancer met Amsterdam criteria, compared with 49% of LS families without breast cancer (p=0.03). Lifetime cumulative incidence of breast cancer in female <jats:italic>MSH2<\/jats:italic> mutation carriers in our cohort was 22% (p&lt;0.001). The SIR for breast cancer of female <jats:italic>MSH2<\/jats:italic> mutation carriers in our cohort was 3.11 (95% CI 1.95 to 4.71).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>An increased risk of breast cancer in <jats:italic>MSH2<\/jats:italic> mutation carriers was demonstrated in a Canadian familial cancer registry. Women with breast cancer often had a personal and family history of multiple LS-related malignancies. These results suggest a potential role for intensified breast cancer surveillance among women with LS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2017-104542","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T20:50:17Z","timestamp":1501879817000},"page":"742-746","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry"],"prefix":"10.1136","volume":"54","author":[{"given":"Mira","family":"Goldberg","sequence":"first","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melyssa","family":"Aronson","sequence":"additional","affiliation":[{"name":"Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Semotiuk","sequence":"additional","affiliation":[{"name":"Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Pond","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gallinger","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary and Pancreatic Surgical Oncology, Toronto General Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zbuk","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"2025101722101650000_54.11.742.1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1966.03870080050009"},{"key":"2025101722101650000_54.11.742.2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L"},{"key":"2025101722101650000_54.11.742.3","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22262"},{"key":"2025101722101650000_54.11.742.4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10689-012-9562-2","article-title":"Is the controversy on breast Cancer as part of the Lynch-related tumor spectrum still open?","volume":"11","author":"Grandval","year":"2012","journal-title":"Fam Cancer"},{"key":"2025101722101650000_54.11.742.5","first-page":"1014","article-title":"Exclusion of breast Cancer as an integral tumor of hereditary nonpolyposis colorectal Cancer","volume":"62","author":"M\u00fcller","year":"2002","journal-title":"Cancer Res"},{"key":"2025101722101650000_54.11.742.6","doi-asserted-by":"publisher","DOI":"10.1086\/320610"},{"key":"2025101722101650000_54.11.742.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23508"},{"key":"2025101722101650000_54.11.742.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.2278"},{"key":"2025101722101650000_54.11.742.9","doi-asserted-by":"publisher","DOI":"10.1086\/316942"},{"key":"2025101722101650000_54.11.742.10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs351"},{"key":"2025101722101650000_54.11.742.11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs525"},{"key":"2025101722101650000_54.11.742.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-007-9164-6"},{"key":"2025101722101650000_54.11.742.13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/tbj.12077","article-title":"Loss of mismatch repair protein expression in breast carcinoma in patients with Lynch syndrome: report of two cases","volume":"19","author":"Beggs","year":"2013","journal-title":"Breast J"},{"key":"2025101722101650000_54.11.742.14","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006030116357"},{"key":"2025101722101650000_54.11.742.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.08.025"},{"key":"2025101722101650000_54.11.742.16","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1186\/1897-4287-9-S1-P1","article-title":"Lynch syndrome - is breast Cancer a feature?","volume":"9","author":"Catts","year":"2011","journal-title":"Hered Cancer Clin Pract"},{"key":"2025101722101650000_54.11.742.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5590"},{"key":"2025101722101650000_54.11.742.18","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103216"},{"key":"2025101722101650000_54.11.742.19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3405"},{"key":"2025101722101650000_54.11.742.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-007-9174-4"},{"key":"2025101722101650000_54.11.742.21","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20935"},{"key":"2025101722101650000_54.11.742.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0449-3"},{"key":"2025101722101650000_54.11.742.23","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3205"},{"key":"2025101722101650000_54.11.742.24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1836::AID-CNCR12>3.0.CO;2-0"},{"key":"2025101722101650000_54.11.742.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3058"},{"key":"2025101722101650000_54.11.742.26","unstructured":"Kaushik PEB , Moyes K , Landon M , et al , 2014. Clinical Presentations of MMR mutation positive patients with no personal or family history of colon or endometrial cancer. Collaborative Group of the Americas on Inherited Colorectal Cancer, New Orleans,\u00a0LA. 2014"},{"key":"2025101722101650000_54.11.742.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70168-5"},{"key":"2025101722101650000_54.11.742.28","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","article-title":"BRCA in breast Cancer: esmo clinical Practice guidelines","volume":"22 Suppl 6","author":"Balma\u00f1a","year":"2011","journal-title":"Ann Oncol"},{"key":"2025101722101650000_54.11.742.29","unstructured":"Statistics Canada: table 103-0550 - New cases of primary Cancer (based on February 2014 CCR tabulation file), by Cancer type, age group and sex, Canada, provinces and territories, annual, CANSIM (database). 2014. http:\/\/www5.statcan.gc.ca\/cansim\/home-accueil?lang=eng; (accessed July 2017)."},{"key":"2025101722101650000_54.11.742.30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/oxfordjournals.aje.a009371","article-title":"Maximum (Max) and Mid-P confidence intervals and p values for the standardized mortality and incidence ratios","volume":"147","author":"Kulkarni","year":"1998","journal-title":"Am J Epidemiol"},{"key":"2025101722101650000_54.11.742.31","unstructured":"Canadian Cancer society\u2019s Advisory Committee on Cancer Statistics. http:\/\/www.cancer.ca\/~\/media\/cancer.ca\/CW\/cancer information\/cancer 101\/Canadian cancer statistics\/Canadian-Cancer-Statistics-2014-EN.pdf (accessed 29 Jun 2016)."},{"key":"2025101722101650000_54.11.742.32","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high risk assessment: breast and ovarian (Version 2.2016). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf (accessed 29 Jun 2016)."},{"key":"2025101722101650000_54.11.742.33","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.2.75"},{"key":"2025101722101650000_54.11.742.34","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2001.19.20.4074","article-title":"MSH2 mutation carriers are at higher risk of Cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal Cancer families","volume":"19","author":"Vasen","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025101722101650000_54.11.742.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2008.01125.x"},{"key":"2025101722101650000_54.11.742.36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian Cancer genes in more than 1000 patients","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2017-104542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T05:10:25Z","timestamp":1760764225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2017-104542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,10,23]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1136\/jmedgenet-2017-104542"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104542","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}